| HOME >> BIOLOGY >> TECHNOLOGY |
BURLINGTON, N.C. and ROCKVILLE, M.D., June 5 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH), one of the world's leading clinical trials and genetic testing laboratories, and Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced an exclusive alliance to develop and commercialize a series of diagnostic tests for genetic markers identified by Vanda in the course of its clinical development of Fanapta(TM) (iloperidone), a novel atypical antipsychotic drug candidate under FDA review for the treatment of schizophrenia. Financial terms of the agreement were not disclosed.
Vanda has identified a series of pharmacogenetic markers during its development of Fanapta(TM), and the company continues its pioneering work in this area. Under the terms of the collaboration, LabCorp will be Vanda's exclusive commercialization partner for tests for genetic markers of the Fanapta(TM) program.
"Working with innovative companies like Vanda to commercialize
predictive medicine tests is a critical strategic focus for LabCorp," said
Andrew J. Conrad, Ph.D., Chief Scientist and Global Head of Clinical Trials
for LabCorp. "This collaboration is an example of our commitment to the
advancement of personalized medicine and represents a successful
translation of a research based assay into a valuable diagnostic test. This
relationship i
'/>"/>
| SOURCE Vanda Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved |